You are using an outdated browser. For a faster, safer browsing experience, upgrade for free today.

Medical Care

Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Research Report 2021, Competitive Analysis, Industry Growth Trends And Forecast 2027

Market Analysis and Insights: Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market
The research report studies the B-Cell Maturation Antigen(BCMA) Targeted Therapies market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
The global B-Cell Maturation Antigen(BCMA) Targeted Therapies market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Scope and Segment
The global B-Cell Maturation Antigen(BCMA) Targeted Therapies market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global B-Cell Maturation Antigen(BCMA) Targeted Therapies market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2016-2027.
by Type, the market is primarily split into
Bispecific Antibodies
Antibody Drug Conjugates
Chimeric Antigen Receptor T-Cells
by Application, this report covers the following segments
Liver Cancer
Respiratory Cancer
Brain Cancer
Global B-Cell Maturation Antigen(BCMA) Targeted Therapies market: regional analysis, the major regions covered in the report are:
North America
United States
Rest of Europe
South Korea
Southeast Asia
Rest of Asia-Pacific
Latin America
Middle East & Africa
Saudi Arabia
Rest of Middle East & Africa
The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.
The B-Cell Maturation Antigen(BCMA) Targeted Therapies key players in this market include:
Transposagen Biopharmaceuticals
Sutro Biopharma
Malin Corporation
Eureka Therapeutics
firstVentury Equity
Five Prime Therapeutics
Credit Suisse Securities
Dana-Farber Cancer Institute
Deerfield Partners
Onyx Pharmaceuticals
Juno Therapeutics
1 Market Overview of B-Cell Maturation Antigen(BCMA) Targeted Therapies
1.1 B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Overview
1.1.1 B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Scope
1.1.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Status and Outlook
1.2 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size Overview by Region 2016 VS 2021VS 2027
1.3 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Region (2016-2027)
1.4 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Historic Market Size by Region (2016-2021)
1.5 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size Forecast by Region (2022-2027)
1.6 Key Regions, B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size (2016-2027)
1.6.1 North America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size (2016-2027)
1.6.2 Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size (2016-2027)
1.6.3 Asia-Pacific B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size (2016-2027)
1.6.4 Latin America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size (2016-2027)
1.6.5 Middle East & Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size (2016-2027)
2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Overview by Type
2.1 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Type: 2016 VS 2021 VS 2027
2.2 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Historic Market Size by Type (2016-2021)
2.3 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Forecasted Market Size by Type (2022-2027)
2.4 Bispecific Antibodies
2.5 Antibody Drug Conjugates
2.6 Chimeric Antigen Receptor T-Cells
3 B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Overview by Application
3.1 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Application: 2016 VS 2021 VS 2027
3.2 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Historic Market Size by Application (2016-2021)
3.3 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Forecasted Market Size by Application (2022-2027)
3.4 Liver Cancer
3.5 Respiratory Cancer
3.6 Brain Cancer
3.7 Others
4 B-Cell Maturation Antigen(BCMA) Targeted Therapies Competition Analysis by Players
4.1 Global B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Players (2016-2021)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in B-Cell Maturation Antigen(BCMA) Targeted Therapies as of 2020)
4.3 Date of Key Players Enter into B-Cell Maturation Antigen(BCMA) Targeted Therapies Market
4.4 Global Top Players B-Cell Maturation Antigen(BCMA) Targeted Therapies Headquarters and Area Served
4.5 Key Players B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Solution and Service
4.6 Competitive Status
4.6.1 B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles and Key Data
5.1 Transposagen Biopharmaceuticals
5.1.1 Transposagen Biopharmaceuticals Profile
5.1.2 Transposagen Biopharmaceuticals Main Business
5.1.3 Transposagen Biopharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Products, Services and Solutions
5.1.4 Transposagen Biopharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (US$ Million) & (2016-2021)
5.1.5 Transposagen Biopharmaceuticals Recent Developments
5.2 Sutro Biopharma
5.2.1 Sutro Biopharma Profile
5.2.2 Sutro Biopharma Main Business
5.2.3 Sutro Biopharma B-Cell Maturation Antigen(BCMA) Targeted Therapies Products, Services and Solutions
5.2.4 Sutro Biopharma B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (US$ Million) & (2016-2021)
5.2.5 Sutro Biopharma Recent Developments
5.3 Malin Corporation
5.3.1 Malin Corporation Profile
5.3.2 Malin Corporation Main Business
5.3.3 Malin Corporation B-Cell Maturation Antigen(BCMA) Targeted Therapies Products, Services and Solutions
5.3.4 Malin Corporation B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (US$ Million) & (2016-2021)
5.3.5 Eureka Therapeutics Recent Developments
5.4 Eureka Therapeutics
5.4.1 Eureka Therapeutics Profile
5.4.2 Eureka Therapeutics Main Business
5.4.3 Eureka Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Products, Services and Solutions
5.4.4 Eureka Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (US$ Million) & (2016-2021)
5.4.5 Eureka Therapeutics Recent Developments
5.5 firstVentury Equity
5.5.1 firstVentury Equity Profile
5.5.2 firstVentury Equity Main Business
5.5.3 firstVentury Equity B-Cell Maturation Antigen(BCMA) Targeted Therapies Products, Services and Solutions
5.5.4 firstVentury Equity B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (US$ Million) & (2016-2021)
5.5.5 firstVentury Equity Recent Developments
5.6 Five Prime Therapeutics
5.6.1 Five Prime Therapeutics Profile
5.6.2 Five Prime Therapeutics Main Business
5.6.3 Five Prime Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Products, Services and Solutions
5.6.4 Five Prime Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (US$ Million) & (2016-2021)
5.6.5 Five Prime Therapeutics Recent Developments
5.7 Credit Suisse Securities
5.7.1 Credit Suisse Securities Profile
5.7.2 Credit Suisse Securities Main Business
5.7.3 Credit Suisse Securities B-Cell Maturation Antigen(BCMA) Targeted Therapies Products, Services and Solutions
5.7.4 Credit Suisse Securities B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (US$ Million) & (2016-2021)
5.7.5 Credit Suisse Securities Recent Developments
5.8 Dana-Farber Cancer Institute
5.8.1 Dana-Farber Cancer Institute Profile
5.8.2 Dana-Farber Cancer Institute Main Business
5.8.3 Dana-Farber Cancer Institute B-Cell Maturation Antigen(BCMA) Targeted Therapies Products, Services and Solutions
5.8.4 Dana-Farber Cancer Institute B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (US$ Million) & (2016-2021)
5.8.5 Dana-Farber Cancer Institute Recent Developments
5.9 Deerfield Partners
5.9.1 Deerfield Partners Profile
5.9.2 Deerfield Partners Main Business
5.9.3 Deerfield Partners B-Cell Maturation Antigen(BCMA) Targeted Therapies Products, Services and Solutions
5.9.4 Deerfield Partners B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (US$ Million) & (2016-2021)
5.9.5 Deerfield Partners Recent Developments
5.10 Onyx Pharmaceuticals
5.10.1 Onyx Pharmaceuticals Profile
5.10.2 Onyx Pharmaceuticals Main Business
5.10.3 Onyx Pharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Products, Services and Solutions
5.10.4 Onyx Pharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (US$ Million) & (2016-2021)
5.10.5 Onyx Pharmaceuticals Recent Developments
5.11 Juno Therapeutics
5.11.1 Juno Therapeutics Profile
5.11.2 Juno Therapeutics Main Business
5.11.3 Juno Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Products, Services and Solutions
5.11.4 Juno Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (US$ Million) & (2016-2021)
5.11.5 Juno Therapeutics Recent Developments
6 North America
6.1 North America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Country (2016-2027)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Country (2016-2027)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Region (2016-2027)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Country (2016-2027)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size by Country (2016-2027)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Dynamics
11.1 B-Cell Maturation Antigen(BCMA) Targeted Therapies Industry Trends
11.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Drivers
11.3 B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Challenges
11.4 B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
  • PUBLISHED DATE: Apr, 2021
  • NO OF PAGES: 125